INBRX-!09 on the Fast Track for Metastatic Conventional Chondrosarcoma Patients

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

Registration-enabling study expected to begin dosing in the second or third quarter of this year

Contact Information

If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.

**A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**

301-352-3042
info@csfshayna.org

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank You!

Oops, message not sent.

INBRX-!09 on the Fast Track for Metastatic Conventional Chondrosarcoma Patients

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

Contact Information

Send a Message